2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2806

A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
Abstract Number: 1560

A Unique Immune Signature in Patients with Active Rheumatoid Arthritis but Normal C-Reactive Protein Levels: Potential for New Therapeutic Targets?
Abstract Number: 1196

AA Amyloidosis: An Evaluation of Epidemiology and Prevalence in the US and EU5 Countries
Abstract Number: 338

Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline
Abstract Number: 2583

Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Abstract Number: 1041

Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
Abstract Number: 1612

Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis
Abstract Number: 2867

Aberrant Epigenetic Alterations at the Promoter up-Regulate cAMP Responsive Element Modulator Alpha in CD4+ T Cells from Patients with Systemic Lupus Erythematosus
Abstract Number: 277

Abnormal Composition of Circulating T and B Cells in Patients with Polymyositis and Dermatomyositis Is More Biased in Those with Interstitial Lung Diseases
Abstract Number: 3032

Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort
Abstract Number: 2232

Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Abstract Number: 616

ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Abstract Number: 650

ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Abstract Number: 648

ABT-122, an Anti-TNF/Anti-IL-17 Dual Variable Domain Antibody, Alters T Cell Responses in Human Subjects
Abstract Number: 1715

ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses

« Previous Page
1
…
7
8
9
10
11
…
219
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].